5 results on '"Hidaka, Tomonori"'
Search Results
2. Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.
- Author
-
Kameda, Takuro, Shide, Kotaro, Tahira, Yuki, Sekine, Masaaki, Sato, Seiichi, Ishizaki, Junzo, Takeuchi, Masanori, Akizuki, Keiichi, Kamiunten, Ayako, Shimoda, Haruko, Toyama, Takanori, Maeda, Kouichi, Yamashita, Kiyoshi, Kawano, Noriaki, Kawano, Hiroshi, Hidaka, Tomonori, Yamaguchi, Hideki, Kubuki, Yoko, Kitanaka, Akira, and Matsuoka, Hitoshi
- Subjects
ADULT T-cell leukemia ,LYMPHOMAS ,BLOOD urea nitrogen ,SURVIVAL rate ,PROGNOSIS - Abstract
A retrospective chart survey of the clinical features of indolent adult T-cell leukemia/lymphoma (ATL) was conducted in the Miyazaki Prefecture, Japan. This study enrolled 24 smoldering-type ATLs, 10 favorable chronic-type ATLs, and 20 unfavorable chronic-type ATLs diagnosed between 2010 and 2018. Among them, 4, 3, and 10 progressed to acute-type ATLs during their clinical course. The median survival time (MST) in smoldering-type ATL and favorable chronic-type ATL was not reached, and their 4-year overall survival (OS) was 73% and 79%, respectively. Compared with this, the prognosis of unfavorable chronic-type ATL was poor. Its MST was 3.32 years, and the 4-year OS was 46% (p = 0.0095). In addition to the three features that determine the unfavorable characteristics of chronic-type ATL, namely, increased lactate dehydrogenase, increased blood urea nitrogen, and decreased albumin, the high-risk category by the indolent ATL-Prognostic Index, which was defined by an increment of soluble interleukin-2 receptor (sIL2-R) of >6000 U/mL, could explain the poor prognosis in indolent ATL patients. The level of sIL-2R might be an indicator of the initiation of therapy for indolent ATL. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Outcome of allogeneic hematopoietic cell transplantation in patients with adult T-cell leukemia.
- Author
-
Kamiunten, Ayako, Sekine, Masaaki, Kameda, Takuro, Akizuki, Keiichi, Tahira, Yuki, Shide, Kotaro, Shimoda, Haruko, Kato, Koji, Hidaka, Tomonori, Kubuki, Yoko, and Shimoda, Kazuya
- Abstract
Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm, and the outcome of patients with ATL after chemotherapy is poor. Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative treatment modality for ATL, and four factors, namely, age > 50 years, male recipient, lack of complete remission at transplantation, and transplantation of cord blood, were previously shown to be associated with poor survival. We retrospectively analyzed the outcome of 21 patients with ATL who had undergone allo-HSCT at our hospital during a 3-year period. Of 21 patients, all had at least one of the above risk factors, and 18 had two or more. With a median follow-up of 19.7 months for living patients, the 1- and 2-year overall survival (OS) rates after transplantation were 34% and 27%, respectively. All relapse/progression events occurred within 1 year after allo-HSCT, and the cumulative incidence of relapse/progression at 1 year after allo-HSCT was 46.9%. The 100-day and 1-year nonrelapse mortality (NRM) rates were 19% and 42%, respectively. No significant difference in OS was observed between myeloablative and reduced-intensity conditioning regimens. The 3-year OS (27%) of ATL patients who received allo-HSCT and who had at least one adverse factor was somewhat poorer than the 3-year OS of 33% identified in a nationwide study of allo-HSCT in ATL patients in Japan. The high relapse/progression and NRM rates are major problems to be solved to achieve better outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
- Author
-
Sekine, Masaaki, Kubuki, Yoko, Kameda, Takuro, Takeuchi, Masanori, Toyama, Takanori, Kawano, Noriaki, Maeda, Kouichi, Sato, Seiichi, Ishizaki, Junzo, Kawano, Hiroshi, Kamiunten, Ayako, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Shide, Kotaro, Hidaka, Tomonori, Kitanaka, Akira, Yamashita, Kiyoshi, Matsuoka, Hitoshi, and Shimoda, Kazuya
- Subjects
ADULT T-cell leukemia ,T-cell lymphoma ,THERAPEUTIC use of monoclonal antibodies ,PROGRESSION-free survival ,ANTINEOPLASTIC agents ,LEUKEMIA treatment ,THERAPEUTICS - Abstract
Objective The efficacy of mogamulizumab in adult T-cell leukemia/lymphoma ( ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes. Method We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. Results Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival ( PFS) and overall survival ( OS) from the start of mogamulizumab therapy were 1.8 and 4.0 months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5 months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12 months, longer than the 5.8 months in a historical cohort without mogamulizumab. Conclusion In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
- Author
-
Shimosaki, Shunsuke, Nakahata, Shingo, Ichikawa, Tomonaga, Kitanaka, Akira, Kameda, Takuro, Hidaka, Tomonori, Kubuki, Yoko, Kurosawa, Gene, Zhang, Lilin, Sudo, Yukio, Shimoda, Kazuya, and Morishita, Kazuhiro
- Subjects
- *
T-cell lymphoma , *INTERLEUKIN-2 , *IRON metabolism , *THERAPEUTIC use of monoclonal antibodies , *TRANSFERRIN receptors , *ANTIBODY-dependent cell cytotoxicity - Abstract
Iron is an essential nutrient for normal cell growth, and reprogramming of iron metabolism is essential to tumor cell survival and progression. HTLV-1-associated adult T-cell leukemia/lymphoma (ATLL) has no effective therapy and high levels of cell surface transferrin receptor 1 (TFR1) expression have been reported in ATLL by us and other groups. In this study, to develop a novel molecular-targeted therapy against TFR1 to modulate iron metabolism, we initially determined the expression pattern of several iron-related genes along with TFR1 and found that ATLL cells presented characteristic of an iron-deficiency state such as high expression of iron-regulatory protein 2 (IRP2) and low expression of its E3 ubiquitin-ligase, FBXL5. Therefore, we developed human IgG monoclonal antibodies to human TFR1 using a phage display method (ICOS method) to block the incorporation of the transferrin (TF)-iron complex into ATLL cells for inhibiting cell growth. One of the mAbs, JST-TFR09, presented its greater affinity to TFR1 on ATLL cells in flow cytometry (FCM) analysis than those of commercially available anti-TFR1 antibodies and identified high expression of TFR1 in most of the acute-type ATLL cells. Moreover, JST-TFR09 could interfere with binding between TFR1 and TF, which resulted in effective blockade of TFR1 internalization and induction of cell apoptosis by the treatment of ATLL cells with JST-TFR09. JST-TFR09 showed dual activities through direct cell cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC), and the treatment of JST-TFR09 significantly suppressed cell growth of ATLL cells with induction of apoptosis in in vitro and in vivo experiments. Thus, JST-TFR09 described here may become a promising therapeutic antibody for the treatment of ATLL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.